Universiteit Leiden

nl en

Mario van der Stelt

Associate professor

Name
Dr. M. van der Stelt
Telephone
+31 71 527 4768
E-mail
m.van.der.stelt@chem.leidenuniv.nl

There are still many life-threatening diseases, such as Alzheimer’s disease, metabolic syndrome and cancer, for which there are no suitable therapies available. Mario van der Stelt aims to discover new molecules that can act as drug candidates for these type of diseases.

More information about Mario van der Stelt

Curriculum Vitae

Personal information

Nationality:   Dutch
Date of birth:   20 September 1975

Education

2002   PhD, Faculty of Chemistry, Utrecht University, The Netherlands, 12 April 2002 (cum laude)
Thesis title: ‘The Endocannabinoid Anandamide. Metabolism & Neuroprotection’
Advisors: Prof. J.F.G. Vliegenthart, Prof. G.A. Veldink
1998   MSc in Chemistry, Faculty of Chemistry, Utrecht University, The Netherlands (cum laude)

Current and previous research positions

2012 – now     Tenure Track Associate Professor, Leiden Institute of Chemistry, Leiden University, The Netherlands
2004 – 2012   Project-leader of drug discovery teams at Merck Research Laboratories, Oss, The Netherlands
2002 – 2004   Post-doctoral Researcher, Endocannabinoid Research Group, Institute of Bio-organic Chemistry, Pozzuoli, Italy (Prof. Dr. V. Di Marzo)

Grants, awards, recognitions since 2010

2017   ICRS 2017 Young Investigator Award
2016   ZonMw Middelgroot grant (co-applicant), main applicant N.S. Pannu (k€ 372)
2016   Hoffman-La Roche (k€ 145)
2015   NWO NCI-TA Grant with Ovaa/Neefjes (NKI/LUMC) (k€ 576)
2015   Roche Post-doc Fellowship program with Prof. Dr. A.P. IJzerman (LACDR) (k€ 233)
2014   NWO-CW ECHO Grant (k€ 260)
2014   Gravitation grant, Institute of Chemical Immunology (k€ 305)
2013   NWO-CW ECHO-STIP Grant (k€ 260)
2013   EU Innovative Medicines Initiative: European Lead Factory with H.S. Overkleeft (k€ 829)

Contribution to teaching and supervision since 2012

  • Coordinator and Lecturer of MSc course for students of Molecular Science and Technology (MST), Life Science and Technology (LST) and BioPharmaceutical Sciences (BPS): Advanced Medicinal Chemistry
  • Lecturer of Honours Class, Leiden University
  • Lecturer of two MSc courses of MST and LST: Modern Drug Discovery and Chemical Genetics
  • Coordinator and Lecturer of BSc course for students of BPS: Design and Synthesis

Supervision of 18 PhD-students, 4 post-doctoral fellows, 1 research technician and 22 MSc students and 16 BSc students

Other responsibilities since 2012

  • ŸFounder and head of the department of Molecular Physiology (2016)
  • ŸOrganisation Conference of the International Cannabinoid Research Society (ICRS) in 2018.
  • ŸChairman of Cancer Drug Discovery Initiative (2014). This is a public private collaboration of Leiden University with the Netherlands Cancer Institute and the Pivot Park Screening Centre and three small medium enterprises (Covalution Pharma, Lead Pharma and NTRC)
  • ŸCo-founder of the European Lead Factory, the largest public private partnership in Europe in the area of drug discovery (2013)
  • ŸCoordinator Faculty Profiling Program Endocannabinoids (2013).
  • ŸMember Program Committee CHAINS (2016) –With as much as 1500 participants, CHAINS is the largest scientific chemistry congress in the Netherlands
  • ŸBoard member of the Netherlands Research Council Chemical Sciences, Study group Pharmacochemistry (2015)
  • ŸMember of Local Animal Welfare Body (2015)
  • ŸMember PhD Supervision Board of Leiden Academic Centre for Drug Research
  • ŸReview editor of Frontiers in Chemistry, Chemical Biology, Review editor of Frontiers in Neuroscience;
  • ŸMember editorial board Cannabis, & Cannabinoid Research;
  • ŸRegular reviewer for international grant applications and member of PhD-evaluation committees
  • ŸReviewer for various journals, including Nature Chemical Biology, Journal of American Chemical Society, Journal of Medicinal Chemistry and Chemical Science

Publication record including five recent representative publications

> 50 papers and book chapters > 3900 citations (average of 76 citations/article), 6 patents, h-index = 24 (Google Scholar). Full publication record: Leiden University

  • Esbroeck A.C.M. van, Janssen A.P.A., Cognetta A.B. 3rd, Ogasawara D., Shpak G., Kroeg M. van der, Kantae V., Baggelaar M.P., Vrij F.M.S. de, Deng H., Allarà M., Fezza F., Lin Z., Wel T. van der, Soethoudt M., Mock E.D., Dulk H. den, Baak I.L., Florea B.I., Hendriks G., De Petrocellis L., Overkleeft H.S., Hankemeier T., Zeeuw C.I. de, Di Marzo V., Maccarrone M., Cravatt B.F., Kushner S.A., Stelt M. van der, Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 2017, 356, 1084-1087.
  • ŸSoethoudt M., Grether U., Fingerle J., Grim T.W., Fezza F., De Petrocellis L., Ullmer C., Rothenhäusler B., Perret C., Can Gils N., Finlay D., MacDonald C., Chicca C., Dalghi Gens M., Stuart J., Vries H. de, Mastrangelo N., Xia L., Alachouzos G., Baggelaar M.P., Martella A., Mock E.D., Deng H., Heitman L.H., Connor M., Di Marzo V., Gertsch J., Lichtman A., Maccarrone M., Pacher P., Glass M., Stelt M. van der, Cannabinoid CB2 Receptor Ligand Profiling Reveals Biased Signaling and Off-target Activity. Nature Comm, 2017, 8, 13958.
  • ŸOgasawara D., Deng H., Viader A., Baggelaar M.P., Breman A., Dulk H. den, Nieuwendijk A.M. van den, Soethoudt M., Wel T. van der, Zhou J., Overkleeft H.S., Sanchez-Alavez M., Mo S., Nguyen W., Conti B., Liu X., Chen Y., Liu Q.S., Cravatt B.F., Stelt M van der., Rapid and profound rewiring of brain lipid signalling networks by acute diacylglycerol lipase inhibition. Proceedings of the National Academy of Sciences of the United States of America. 2016, 113, 26-33.
  • ŸBaggelaar M.P., Chameau P.J., Kantae V., Hummel J., Hsu K.L., Janssen F., Wel T. van der, Soethoudt M., Deng H., Dulk H. den, Allara M., Florea B.I., Di Marzo V., Wadman W.J., Kruse C.G., Overkleeft H.S., Hankemeier T., Werkman T.R., Cravatt B.F., Stelt M. van der, Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons. Journal of the American Chemical Society. 2015, 137, 8851-8857.
  • ŸBaggelaar M.P., Janssen F.J., Esbroeck A.C. van, Dulk H. den, Allara M., Hoogendoorn S., McGuire R., Florea B.I., Meeuwenoord N., Elst H. van den, Marel G.A. van der, Brouwer J., Di Marzo V., Overkleeft H.S., Stelt M. van der, Development of an activity-based probe and in silico design reveal highly selective inhibitors for diacylglycerol lipase-alpha in brain. Angewandte Chemie International Edition. 2013, 52, 12081-12085.

Presentations including five presentations at international conferences since 2012

> 20 presentations at universities, companies and institutes, and invited, keynote and plenary lectures at international conferences since 2012

  • ŸDevelopment of highly selective DAG-lipase inhibitors for in vivo studies, Gordon Conference on Cannabinoid Function in the CNS, May 2015, Lucca, Italy, invited lecture
  • ŸDiscovery of in vivo active and selective diacylglycerol lipase-alpha inhibitor, European Federation of Medicinal Chemistry, August 2016, Manchester, United Kingdom, invited lecture
  • ŸNovel molecular tools to study the biological role of the Endocannabinoid system, Gratama Workshop (Dutch-Japanese Chemistry Conference), March 2013, Tokyo, Japan, keynote lecture

Associate professor

  • Wiskunde en Natuurwetenschappen
  • Leiden Institute of Chemistry
  • LIC/Molecular Physiology

Work address

Science Campus
Einsteinweg 55
2333 CC Leiden
Room number DE319

Contact

Publications

No relevant ancillary activities